11 research outputs found

    Comparative distribution of patient’s demographic, clinical and immunological characteristics in the derivation and validation sets.

    No full text
    <p>The main characteristics of the patients are listed here for the time point of enrollment during PHI (M0). For each parameter (except gender), the median values and the range are indicated. Plasma IP-10 concentrations were measured by ELISA at M0. For the derivation set, data are shown for those 45 patients out of 46, whose IP-10 was quantified by ELISA. The validation set comprised 88 patients. There was no significant difference between the two sets for any parameter (p>0.11). W: women, M: men, N: number of patients in each set.</p

    Plasma protein levels at M0 according to disease progression profiles.

    No full text
    <p>The cytokine profiles at M0 are shown for each group of patients: 16 rapid progressors (<b>A</b>), 19 progressors (<b>B</b>), and 11 slow progressors (<b>C</b>). Color code and statistical analyses are as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046143#pone-0046143-g002" target="_blank">Figure 2</a> (corrected threshold, p<0.005). The dotted horizontal line corresponds to the value in healthy donors. (<b>D</b>) Comparison of protein concentrations between the 3 groups of patients (SP, P and RP). Four representative cytokines are shown. The cytokines increasing significantly over groups were IP-10 and IL-10 (Cuzick’s test, p<0.007). When comparing the groups two by two, out of 28 proteins tested, the levels were different only for IP-10 (M&W test,***: p<0.005).</p

    Plasma protein levels in HIV-1 infected patients.

    No full text
    <p>(<b>A</b>) The levels of 28 proteins in the plasma of 46 acutely infected patients (M0) are expressed as fold change compared to the levels in healthy donors (N = 17). The order of the proteins is presented according to their function (pro-inflammatory, adaptive, IFN-inducible, chemoattractants, hematopoietic and anti-inflammatory). The anti-inflammatory cytokines are presented on the right side of the figure. The dotted horizontal line at Y = 1 corresponds to the value in healthy donors. The boxes represent the median and the 25<sup>th</sup> and 75<sup>th</sup> percentile, with the line in the middle of the boxes corresponding to the median value. Colored boxes stand for the cytokines, whose levels were significantly different from healthy donors: blue boxes when p<0.05 (as it was the case for IL-1ÎČ) and red boxes when p<0.008 (M&W test). (<b>B</b>) Protein concentrations at M0, M1 and M6 of the soluble factors that were elevated at M0. The data are expressed in pg/ml, HD: healthy donors, M: months. Cytokine concentrations below the limit of detection were arbitrarily set at the level of the limit of detection. Dot-plots marked with one asterisk (*) (p<0.05) or two asteriks (**) (p<0.008) represent the cytokines, whose levels were significantly different from healthy donors (M&W test).</p

    Immunological, virological and clinical characteristics of rapid progressors versus progressors and slow progressors assembled within patients of the derivation and validation sets.

    No full text
    <p>The derivation set comprised 46 patients (except for IP-10, where values based on the ELISA were available for only 45 patients). The validation set corresponded to 88 patients for all markers. Differences between rapid progressors and the other patients are indicated with the presence of a p value (M&W test). P values below 0.05 were considered to be significant. There was no significant difference regarding the time of enrollment at M0 (estimated days post-infection). (A) CD4<sup>+</sup> T cells at M0 and M12; (B) Viremia at M0 and M12; (C) number of estimated days post-infection at M0; (D) Plasma IP-10 concentration at M0. M = month.</p

    Cytokines predictive of immunological set-point levels. (A–E)

    No full text
    <p>Cytokine concentrations in plasma at M0 have been plotted against CD4<sup>+</sup> T cell counts and T cell activation (CD3<sup>+</sup>CD8<sup>+</sup>CD38<sup>+</sup>HLA-DR<sup>+</sup>) at M6. Six patients, including 4 who were treated at M6, were excluded from the analysis at M6. T cell activation levels were available for 19 patients at M6 (4 SP, 7 SP, 8 RP). The correlations were thus analyzed in 40 patients regarding CD4<sup>+</sup> T cell counts and viral load and for 19 patients regarding T cell activation. (<b>A</b>) IP-10 levels at M0 plotted against T CD4<sup>+</sup> counts at M6. (<b>B</b>) IP-10 levels at M0 plotted against T cell activation at M6. (<b>C</b>) IL-18 levels at M0 plotted against T cell activation at M6. (<b>D)</b> TGF-ÎČ1 concentrations at M0 plotted against T cell activation at M6. The red line indicates that both the Spearman correlation and the linear regression analysis were significant. <b>(E)</b> Regression analysis for evaluation of the capacity of CD4<sup>+</sup> T cell counts, VL and cytokines at M0 to predict rapid disease progression. Values obtained for both the derivation set (Luminex and ELISA) and the validation set are shown. Median values of CD4<sup>+</sup> T cell counts, VL and cytokine levels were used: VL > = 5 log; CD4<570 cells (derivation set); CD4<546 cells (validation set); IP-10> = 869 pg/ml (derivation set, Luminex); IP-10> = 247 pg/ml (derivation set, ELISA); IP-10> = 232 pg/ml (validation set, ELISA).</p

    Evaluation of r-mamu-IFN-α efficacy in AGMs.

    No full text
    <p>(A) <i>In vitro</i> comparison of the induction of ISG expression in AGM (hatched green) <i>versus</i> rhesus macaques (red) PBMCs after 18 h stimulation with 10, 100 or 1000 IU/ml of r-mamu-IFN-α (n = 2 AGMs, n = 2 macaques). <i>Mx1</i> gene expression values were measured by real-time PCR and are expressed as the Log<sub>2</sub> (fold change relative to values before treatment). The experiment was done in triplicate. (B) IFN-α detection in the plasma of SIV-negative (hatched green) and SIV-infected (blue) AGMs after a single subcutaneous injection of 5×10<sup>5</sup> IU of r-mamu-IFN-α. IFN-α was rapidly detectable in blood (1 h), but decreased after 24 h. (C) Efficient induction of ISG (<i>CXCL10</i>, <i>IP-10</i>) in the PBMC of SIV-negative (hatched green) and SIV-infected (blue) AGMs (chronic phase) after a single subcutaneous injection of 5×10<sup>5</sup> IU of r-mamu-IFN-α. Gene expression was measured by real-time PCR and expressed as the Log<sub>2</sub> (fold change relative to values before treatment). (D) Viral load in a chronically SIV-infected AGM treated during 16 days with r-mamu-IFN-α as described in results. (E) Impact of the r-mamu-IFN-α treatment during acute infection on viral load. SIVagm-infected untreated AGMs are shown in black and IFN-α-treated in blue. Plasma viral load are reported as log<sub>10</sub> (viral RNA copies)/ml of plasma. (F) No major effect of the two weeks IFN-α treatment on T cell proliferation in an uninfected AGM and in a chronically infected AGM (same AGM as in D) as measured by flow cytometry. (G and H) No effect of the treatment during the acute phase on T cell proliferation. T cell proliferations are shown as percentage of Ki-67<sup>+</sup> cells among blood (G) CD4<sup>+</sup> and (H) CD8<sup>+</sup> T cells. SIVagm-infected untreated AGMs are shown in black and IFN-α-treated in blue. The grey area indicates the period of treatment. The medians of treated animals were inside the interquartile range of the control untreated animals and were thus considered not different.</p

    High dose of IFN-α in the acute phase of infection does not induce persistent ISG expression in AGMs.

    No full text
    <p>The 6 panels show the expression levels in PBMCs and LN cells of 3 ISGs: (A,B) <i>CXCL9</i>, (C,D) <i>CXCL10</i> (<i>IP-10</i>) and (E,F) <i>CXCL11</i>. Gene expression was measured by real-time PCR and expressed as the Log<sub>2</sub> (fold change relative to values before treatment). IFN-α treated AGMs are in blue and untreated in black. The grey area indicates the period of treatment. The medians of treated animals were inside the interquartile range of the untreated animals and were thus considered not different.</p

    Profiles of early cytokines in plasma and lymph node supernatants upon SIVagm infection.

    No full text
    <p>Cytokine concentrations in plasma (n = 14 AGMs) and LN cell supernatants (n = 6 AGMs), as determined by ELISA or by a functional test for IFN-α: (A, B) IL-15, (C, D) IFN-α, (E, F) IP-10 and (G, H) MCP-1. The graphs are listed by order of appearance of the cytokines as described for pathogenic HIV infection <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1004241#ppat.1004241-Stacey1" target="_blank">[43]</a>. Only cytokines known to be induced very early on in HIV infection are shown. The horizontal line in each box plot represents the median. The bottom and top edges of each box correspond to the 25th and 75th percentiles. Whiskers extend up to adjacent values representing the largest and smallest values that are not outliers. Day zero represents the median of all the time points before infection. Red and hatched boxes indicate statistically significant increases relative to baseline with p<0.001 and 0.001</p

    Follow-up of homing and maturation markers on pDCs in blood and lymph nodes following SIVagm infection.

    No full text
    <p>PDCs were defined as shown in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1004241#ppat.1004241.s001" target="_blank">Figure S1</a>. Expression levels of the chemokine receptors (A, B) CXCR3 and (C, D) CCR7 and the (E, F) co-stimulatory CD86 on (A, C, E) blood and (B, D, F) LN pDCs are shown as MFI after substraction of isotype-control values (n = 6 AGMs). The expression levels of (G) HLA-DR and (H) CD40 were analyzed on another group of 8 AGMs. PDCs were here defined as CD20<sup>−</sup> BDCA2<sup>+</sup> CD123<sup>+</sup> HLA-DR<sup>+</sup>. Data are presented as medians and interquartile ranges. Day zero represents the median of all the time points before infection. See legend to <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1004241#ppat-1004241-g002" target="_blank">Figure 2</a> for a description of p-values (logarithm transformation for panel B).</p

    Expression of homing and maturation marker on mDCs in blood and lymph nodes following SIVagm infection.

    No full text
    <p>MDCs were defined as shown in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1004241#ppat.1004241.s001" target="_blank">Figure S1</a>. Expression levels of the chemokine receptors (A, B) CXCR3 and (C, D) CCR7 and the co-stimulatory (F, G) CD86 and (I, J) CD80 molecules on mDCs by flow cytometry in blood (left panels) and LNs (center panels) are shown as mean fluorescence intensity (MFI) after isotype-control levels were subtracted (n = 6 AGMs). A phenotypic analysis of mDC subsets was performed on another group of 8 AGMs (right panels). CD16 was added to differentiate the subsets. The expression levels of (E) HLA-DR, (H) CD86 and (K) CD80 on CD16<sup>+</sup> (in purple) and CD16<sup>−</sup> (in pink) mDCs are shown as MFI. Data are presented as medians and interquartile ranges. Day zero represents the median of all the time points before infection. P-values were obtained from a linear mixed effect model to characterize each marker's progression (with a logarithm transformation for panel A and B).</p
    corecore